CClinicalTrials.gg
CompletedNCT03784495MelAASarcUpdated Dec 24, 2018

Melatonin Plus Aminoacids for Sarcopenic Elderly

An interventional study of Melatonin 1mg and Essential Aminoacids (eAA) in Sarcopenia, sponsored by Azienda di Servizi alla Persona di Pavia. Completed at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-12-24.

Sponsored by Azienda di Servizi alla Persona di Pavia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled Jan 2014, registered Dec 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

To evaluate the effectiveness of melatonin and essential aminoacid supplementation on body composition, protein metabolism, strength and inflammation. The investigators performed a Randomized controlled parallel groups preliminary trial in 159 elderly sarcopenic people (42/117 men/women) assigned to 4 groups: isocaloric placebo (P, n=44), melatonin (M, 1 mg/daily, n=42,), essential aminoacids (eAA 4 g/daily, n=40) or eAA plus melatonin (eAAM, 4 g eAA and 1 mg melatonin/daily, n= 30). The period of intervention was 4 weeks. Data from body composition (DXA), strength (handgrip test) and biochemical parameters for the assessment of protein metabolism (albumin) and inflammation (PRC) were collected at baseline and after the 4-week intervention

02

Conditions studied

  • Sarcopenia

Browse trials for

03

In context

Sarcopenia

1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.

This study's enrollment of 159 is above the median of 60 across 775 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Azienda di Servizi alla Persona di Pavia is the lead sponsor of 27 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged > or equal 65 years
  • Sarcopenic patients, following the Rosetta Study criteria: Skeletal Muscle Index [SMI] was \<7.23 kg/m2 in men and \<5.45 kg/m2 in women) and loss of strength, evaluated by dynamometer and defined as \<30 kg for men and \<20 kg for women, using the average value of the two handgrip measurements of the dominant hand.

Exclusion criteria

Exclusion Criteria:

  • acute illnesses
  • severe liver dysfunction
  • severe heart dysfunction
  • severe kidney dysfunction
  • severe dementia
  • uncontrolled diabetes
  • dysthyroidism
  • any endocrinopathies
  • neoplasia
  • patients treated with steroids
  • patients entirely unable to walk
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
159 participants (actual)

Study arms

  • Placebo comparator
    Placebo (P)

    Placebo.

    Other: Placebo

  • Experimental
    Melatonin (M)

    1 mg/day of melatonin.

    Drug: Melatonin 1mg

  • Experimental
    Essential Aminoacids (eAA)

    4 g/day of essential aminoacids

    Dietary Supplement: Essential Aminoacids (eAA)

  • Experimental
    Essential Aminoacids + Melatonin (eAAM)

    4 g/day of essential aminoacids and 1 mg/day of melatonin

    Combination Product: Essential Aminoacids + melatonin

Interventions

  • DrugMelatonin 1mg

    1 mg/day 30 minutes before sleep

  • Dietary supplementEssential Aminoacids (eAA)

    4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.

  • Combination productEssential Aminoacids + melatonin

    4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.

  • OtherPlacebo

    an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product

06

What researchers measure

Primary outcomes

  1. Change in Total Fat Mass and Total Free Fat Mass (DXA)

    Body composition by dual-energy X-ray absorptiometry (DXA). Body composition was measured by DXA, using a Lunar Prodigy DXA (GE Medical Systems, Waukesha, WI). Free Fat mass and Fat mass of specific body regions were measured in kilograms.

    Time frame: 0, 30 days

  2. Change in Handgrip Strenght

    Handgrip strength assessed using a Jamar dynamometer adhering to the standardized protocol recommended by the American Society of Hand Therapists. A weak handgrip was defined as \<30 kg for men and \<20 kg for women, based on the average value of the two handgrip measurements of the dominant hand

    Time frame: 0, 30 days

Secondary outcomes

  1. Height

    Height measured in meters

    Time frame: At baseline (0)

  2. Change in Body Weight

    Body Weight measured in kilograms

    Time frame: 0, 30 days

  3. Change in serum proteins

    Serum proteins and albumin were measured by automatic biochemical analyzer. They were reported as g/dl

    Time frame: 0, 30 days

  4. Change in blood lipids (total cholesterol and triglycerides)

    Blood lipids (total cholesterol and triglycerides)were measured by automatic biochemical analyzer. They were reported as mg/dl

    Time frame: 0, 30 days

  5. Change in High-sensitivity C-reactive protein (CRP)

    High-sensitivity C-reactive protein (CRP) was expressed in mg/dl.

    Time frame: 0, 30 days

  6. Change in erythrocyte sedimentation rate (ESR)

    Erythrocyte sedimentation rate (ESR) was expressed in mm/hr.

    Time frame: 0, 30 days

  7. Change in glycaemia

    glycemia was expressed in mg/dl

    Time frame: 0, 30 days

  8. Change in Mini Nutritional Assessment (MNA)

    A mini nutritional assessment (MNA) was performed for all participants. The MNA uses 18 questions regarding simple measurements and a brief questionnaire involving an anthropometric assessment (weight, height and weight loss), a general assessment (lifestyle, medication and mobility), and a dietary assessment (number of meals, food and fluid intake, self-assessment of eating autonomy and self-perception of health and nutrition). Every answer give up to a maximum of 3 points. The sum of all points gives the total MNA. A maximum of 30 points can be achieved. A score of ≥ 24 points describes a well-nourished status. A score of 17 to 23.5 points indicates a risk of malnutrition, while less than 17 points indicates malnutrition.

    Time frame: 0, 30 days

  9. Change in dietary intake

    A trained dietitian used a calibrated dietetic spring scale to weigh all foods served and returned for 3 consecutive days at the beginning and end of the study

    Time frame: Measures taken at day 1,2,3 and at day 28,29,30

07

Study locations

1 site
  • Geriatric physical medicine and rehabilitation division at the Istituto Santa Margherita - Azienda di Servizi alla Persona di Pavia
    Pavia, 27100, Italy
08

References and documents

Individual participant data

Plan to share: No — IPD will be not available for other researchers

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03784495
Lead sponsor
Azienda di Servizi alla Persona di Pavia
Responsible party
Mariangela Rondanelli (MD, Associate Professor, Azienda di Servizi alla Persona di Pavia) — Principal investigator
First posted
Dec 24, 2018
Start date
Jan 1, 2014
Primary completion
Dec 31, 2014
Completion
Jun 1, 2015
Last update
Dec 24, 2018

Study contacts

Mariangela Rondanelli, Professor
study director · IRCCS Mondino Foundation, Pavia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion